Russell Horning
Psychiatric/Mental Health · Phoenix, AZNPI 1669526158
Payments from drug & device makers
Across 814 payments — averaging $312.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$145K
- AbbVie$95K
- Otsuka America Pharmaceutical, Inc.$7K
- Corium, LLC$1K
- Supernus Pharmaceuticals, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $4K from 22 others
What the payments were for
- Consulting fees$1,9251%
- Speaking & faculty fees$217,72586%
- Travel & lodging$19,6058%
- Food & beverage$14,8486%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 212 | $144,696 |
| AbbVie(2 entities) | 250 | $94,937 |
| Otsuka America Pharmaceutical, Inc. | 59 | $6,812 |
| Corium, LLC | 35 | $1,351 |
| Supernus Pharmaceuticals, Inc. | 30 | $1,164 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 54 | $1,152 |
| Alkermes, Inc. | 21 | $596 |
| Lundbeck LLC | 48 | $581 |
| Neurocrine Biosciences, Inc. | 9 | $425 |
| Almatica Pharma LLC | 24 | $417 |
| Axsome Therapeutics, Inc. | 15 | $333 |
| Braeburn Inc. | 8 | $311 |
| E.r. Squibb & Sons, L.L.C. | 8 | $264 |
| Vanda Pharmaceuticals Inc. | 4 | $188 |
| Indivior Inc. | 7 | $164 |
| Janssen Scientific Affairs, LLC | 2 | $162 |
| Teva Pharmaceuticals USA, Inc. | 1 | $116 |
| Boston Scientific | 6 | $101 |
| Idorsia Pharmaceuticals US Inc | 5 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Neos Therapeutics, LP | 3 | $45 |
| Ironshore Pharmaceuticals Inc. | 3 | $43 |
| Collegium Pharmaceutical, Inc. | 3 | $42 |
| Tris Pharma Inc | 1 | $25 |
| Bausch Health US, LLC | 1 | $23 |
| Tempus AI, Inc | 1 | $16 |
| Biogen | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$254,130 in reported general payments places this provider in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 91 | $147,988 |
| RexultiBrexpiprazole | 31 | $64,190 |
| VraylarCariprazine Hcl | 19 | $29,410 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 96 | $10,937 |
| TrintellixVortioxetine Hydrobromide | 12 | $7,592 |
| Divalproex Sodium ErDivalproex Sodium | 27 | $2,316 |
| Duloxetine Hcl | 55 | $1,892 |
| Quetiapine Fumarate | 114 | $1,520 |
| Hydroxyzine Hcl | 15 | $992 |
| Modafinil | 24 | $944 |
| Trazodone Hcl | 75 | $931 |
| Bupropion Hcl SrBupropion Hcl | 57 | $928 |
| Aripiprazole | 25 | $857 |
| Clonazepam | 64 | $736 |
| Prazosin Hcl | 49 | $729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $144,696 | $147,98891 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $6,812 | $64,19031 claims |
| AbbVieVraylar | $94,937 | $29,41019 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $47 | $7,59212 claims |
| Almatica Pharma LLCSertraline Hcl | $417 | $17851 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.
Other psychiatric/mental health in Phoenix
- Elizabeth ElliottPhoenix$363K
- Claire ReecePhoenix$88K
- Luis FongPhoenix$59K
- Marilizabeth BirkPhoenix$34K
- Jaime LecomtePhoenix$15K
- Roger MayorgaPhoenix$10K
- Elena SassPhoenix$9K
- Martha SerranoPhoenix$8K
- Bonnie VogesPhoenix$7K
- Brandy HammondPhoenix$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.